More Alzheimer's Drug Trial Failures: Are Researchers on the Wrong Track?

WEDNESDAY, April 10, 2019 — Amyloid beta has long been a prime suspect in Alzheimer’s disease, since abnormal levels of the protein form disruptive plaques between patients’ brain cells.
But drug trials aimed at lowering amyloid levels have…
Source: Topamax